One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Rapid Diagnostic Kits Market

[ 英語タイトル ] Rapid Diagnostic Kits Market Share - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0083121
Survey : Mordor Intelligence
Publish On : November, 2020
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - ACON Laboratories Inc.
- Abbott Laboratories
- Alfa Scientific Designs Inc.
- Artron Laboratories Inc.
- Becton, Dickinson and Company
- BTNX Inc.
- Meridian Bioscience Inc.
- Creative Diagnostics
- F. Hoffmann-La Roche Ltd
- Zoetis Inc.
- BioMerieux

[Report Description]

The propelling factors for the growth of the rapid diagnostic kits market include the increasing number of government initiatives for the diagnosis of infectious disease incidence, along with the rising need for fast detection of diseases, which are also contributing to the increasing demand for rapid diagnostic tests, across the world. In addition to this, the growth of government initiatives, such as awareness programs and funding research studies, has influenced the healthcare industry.

The government proactively invests in many of the research studies that include the diagnosis of infectious diseases. Thus, increasing government initiatives for the efficient diagnosis of infectious diseases help in driving the overall growth of the market studied.

The patients suffering from chronic diseases are found to have an increased risk of developing end-stage heart failure diseases. Therefore, the early identification and management of patients with chronic diseases are found to be important, in order to decrease morbidity and mortality. The early detection of diseases is possible with the screening programs targeting high-risk patients, such as patients with diabetes mellitus, hypertension, and elderly patients. Thus, there are several rapid diagnostic kits available for many chronic diseases, which diagnose the disease while it is asymptomatic, with no signs or symptoms.

The increase in home healthcare is driving the use of rapid diagnostics. This brings treatment and prevention care options to the patient’s home, thus, avoiding the long queue in hospitals. This saves the patients' time and travel costs, thereby, driving the rapid diagnostics kits market.

Key Market Trends

Veterinary testing is the segment under application that is expected to grow the fastest during the forecast period

There are several rapid diagnostic kits available in the market for veterinary testing. The range of different innovative technologies is available for real-time or rapid diagnosis of livestock diseases. The major advantage of rapid diagnostic kits is the cost, as costs less to test pets and other veterinary animals. All these benefits of rapid diagnostics kits are driving the veterinary segment of the market studied, which is expected to grow further during the forecast period.

The use of kits in-home healthcare testing is also increasing every day, and no special skill is required to use the kits so patients can perform rapid diagnostic tests at home with the help of these kits, which are readily available in the market. Such benefits of the kits and the increasing adoption of the same by people are expected to help the market studied grow during the forecast period.

Asia-Pacific registered the fastest growth and is expected to follow the same trend over the forecast period

The Asia-Pacific region is predicted to witness high growth, due to the presence of a large base of patients with unmet medical needs in emerging economies, such as India and China. This is expected to help the Asia-Pacific rapid medical diagnostic kits market grow at the fastest rate during the forecast period. The increasing number of local manufacturers of RDT kits and the rising disease prevalence are propelling the need for rapid diagnostics, in turn, boosting the market growth over the forecast period.

Competitive Landscape

The rapid diagnostic kits market has leading companies, like Alere, BioMérieux, and Roche Diagnostics, among others. There are also several companies entering into the market. Also, several private companies are introducing innovative products to enter into the market. Various major companies based in the country have also contributed significantly to the market.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Government Initiatives for the Diagnosis of infectious Diseases
4.2.2 Rising Awareness Regarding Early Diagnosis among People
4.2.3 Shift in Technological and Commercial Environment
4.3 Market Restraints
4.3.1 Lack of Awareness Regarding Newer Rapid Diagnostic Tests
4.3.2 Failure to Eliminate the Need for Microscopy Diagnosis
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Technology
5.1.1 Flow Through
5.1.2 Solid Phase
5.1.3 Lateral Flow
5.1.4 Agglutination Assays
5.2 By Application
5.2.1 Hospitals and Clinical Testing
5.2.2 Home Testing
5.2.3 Veterinary Testing
5.3 Geography
5.3.1 North America United States Canada Mexico
5.3.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.3.3 Asia-Pacific China Japan India Australia South korea Rest of Asia-Pacific
5.3.4 Middle East & Africa GCC South Africa Rest of Middle East & Africa
5.3.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 ACON Laboratories Inc.
6.1.2 Abbott Laboratories
6.1.3 Alfa Scientific Designs Inc.
6.1.4 Artron Laboratories Inc.
6.1.5 Becton, Dickinson and Company
6.1.6 BTNX Inc.
6.1.7 Meridian Bioscience Inc.
6.1.8 Creative Diagnostics
6.1.9 F. Hoffmann-La Roche Ltd
6.1.10 Zoetis Inc.
6.1.11 BioMerieux




Recommended reports